AI assistant
Mendus — AGM Information 2022
Nov 10, 2022
3163_rns_2022-11-10_bc5ae669-34fd-4c82-973d-65fe4ac0d27c.pdf
AGM Information
Open in viewerOpens in your device viewer
Press Release
Stockholm, Sweden, 10 November 2022
Mendus announces Nomination Committee for the 2023 Annual General Meeting
Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the principles for appointment of the Nomination Committee, adopted by the Annual General Meeting of May 4, 2021. The members of Mendus' Nomination Committee shall be appointed by the four largest shareholders, as of August 31, 2022, who wish to exercise their right to appoint a representative.
The Chairman of the Board of Directors of Mendus, Christine Lind, has contacted the largest shareholders in order to appoint a Nomination Committee. The following members have been appointed by the four largest shareholders who have accepted the invitation to participate in the Nomination Committee:
Erik Esveld, appointed by Van Herk Investments B.V Jannis Kitsakis, appointed by The Fourth Swedish National Pension Fund Gunnar Hörnsten, appointed by Loggen Invest AB Mats Andersson, appointed by Holger Blomstrand Byggnads AB
In total, the Nomination Committee represents approximately 55.9 per cent of the total number of shares and votes in the company as of August 31, 2022.
The Annual General Meeting will be held on May 12, 2023 in Stockholm.
Information regarding the work of the Nomination Committee is available on Mendus' website www.mendus.com.
Shareholders wishing to make proposals to the Nomination Committee should submit their proposal in writing via e-mail to [email protected] or by letter to Mendus AB (publ), Västra Trädgårdsgatan 15, 111 53 Stockholm, Sweden.
FOR MORE INFORMATION, PLEASE CONTACT:
Christine Lind Chairman of the Board of Directors E-mail: [email protected]
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/